1 / 14

Diabetic Nephropathy Market to 2020

The disease is mainly characterized by macroalbuminuria, where in a single day presence of albumin in the urine increases over 300 milligrams. In addition, diabetic nephropathy is also caused by proteinuria, imbalanced glomerular filtration rate, and hypertension. The imbalanced glomerular filtration rate of the kidney builds up waste products in the blood and increases the level of protein in the urine.

addiethomes
Télécharger la présentation

Diabetic Nephropathy Market to 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DiabeticNephropathyMarket-GlobalStudyonHealthcare Computing:AsiatoWitnessHighestGrowthby2020 Cloud PersistenceMarketResearch GlobalDiabeticNephropathyMarketwill reach$3,145.9millionin2020:Persistence MarketResearch 1 PersistenceMarketResearch

  2. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 PersistenceMarketResearchReleasedNewMarketReport“GlobalMarketStudyonDiabetic NephropathyMarket–AsiatoWitnessHighestGrowthby2020,”.Theglobaldiabetic nephropathymarketwasvaluedatUSD2,262.2millionin2014andisexpectedtogrowata CAGRof5.6%from2014to2020,toreachanexpectedvalueofUSD3,145.9millionin 2020. BrowsethefullGlobalMarketStudyonDiabeticNephropathyMarket:AsiatoWitness HighestGrowthby2020reportathttp://www.persistencemarketresearch.com/market-research/diabetic-nephropathy-market.asp Diabeticnephropathyisadiseaseofthekidneyglomerulusandoneofthemostsignificant complicationsintermsofmortalityandmorbidityforpatientswithdiabetes.Globally,thediabeticnephropathymarketiswitnessingsignificantgrowthduetoincreasingprevalenceofdiabetesandobesityindifferentregionsoftheworld.Inaddition,increasingR&Dinvestmentsindrugdiscoveryanddevelopmentandraisingawarenessaboutdiabetesandkidney-relateddisordersarealsodrivingthegrowthofthemarket.However,stringentregulatoryrequirementsandlongerapprovaltimefordrugsaswellasthelackofcomprehensivetherapeuticmanagementfordiabeticnephropathyareinhibitingthegrowthofdiabeticnephropathymarket.TheglobaldiabeticnephropathymarketisestimatedatUSD2,262.2millionin2014.ItislikelytogrowataCAGRof5.6%from2014to2020toreachUSD3,145.9millionin2020. InNorthAmerica,variousgovernmentprogramsarespreadingawarenessaboutdiabetes andrelatedrenalcomplications.Forinstance,theNationalKidneyDiseaseEducationProgram,oneofthemajorprogramsorganizedbytheU.S.government,forincreasingawarenessaboutthevariouskidneydiseases.Inaddition,thenumberofdiabeticpatientsarealsoincreasingintheregion;accordingtotheSciELOPublicHealth,approximately35millionpeoplewereaffectedwithdiabetesmellitusin2000andthisnumberisexpectedtoreach64millionby2025inNorthAmerica. InEurope,riseinhealthcareexpenditurefordiabetestreatmentandincreasingprevalence ofdiabetesinthevariouspartofEuropeisboostingthegrowthoftheEuropeandiabetic nephropathymarket.AccordingtoIDF,approximately55.4millionpeoplehaddiabetesin 2010andthenumberisexpectedtoreach66.5millionby2030inEurope.Accordingtothe IDF,healthcareexpenditurefordiabetestreatmentwasapproximatelyUSD105.5billionin 2010andisexpectedtoreachUSD124.6billionby2030inEurope. Asiarepresentsthefastestgrowingregioninthediabeticnephropathymarketduetothe riseinadiabeticpopulationinvariouscountriessuchasJapanandtheSoutheastAsiancountries.AccordingtotheInternationalDiabetesFederation(IDF),developingcountries, 2 PersistenceMarketResearch

  3. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 suchasIndiaandChina,areexpectedtohavethehighestnumberofdiabetesmellitus patientscomparedtodevelopedcountries,suchastheU.S.andGermany. Sanofiisoneoftheleadingplayersinthediabeticnephropathymarket.Othermajorplayers indiabeticnephropathymarketincludeEliLillyandCompany,MitsubishiTanabePharmaCorporation,NovartisAG,Pfizer,Inc.,AbbottLaboratories,AbbVie,Inc.,BayerAG,Merck&Co.,Inc.,BayerAGandReataPharmaceuticals,Inc. Theglobaldiabeticnephropathymarketissegmentedasfollows: Diabeticnephropathymarket,bymodeloftreatment DiseaseModifyingTherapies Angiotensin-ConvertingEnzymeInhibitors AngiotensinReceptorBlockers Diuretics CalciumChannelBlockers ReninInhibitors ConnectiveTissueGrowthFactorInhibitors AntioxidantInflammationModulator MonocyteChemoattractantProteinsInhibitor Endothelin-AReceptorAntagonist GProtein-CoupledReceptors           Diabeticnephropathymarket,bygeography NorthAmerica U.S. Canada Europe Germany France U.K. Asia Japan China India RestoftheWorld(RoW) 3 PersistenceMarketResearch

  4. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 MarketHistory: Diabeticnephropathyisadiseaseofthekidneyglomerulusandoneofthemostsignificantcomplications intermsofmortalityandmorbidityforpatientswithdiabetes.Diabeticnephropathyismainlycharacterized bymacroalbuminuria.Thepresenceofover300milligramsofalbuminintheurinein1dayisknownas macroalbuminuria.Globally,thediabeticnephropathymarketiswitnessingsignificantgrowthduetorise intheincidenceofdiabetesandobesityindifferentregionsoftheworld.Inaddition,increasingR&D investmentsindrugdiscoveryanddevelopmentbyvariouscompanies,suchasSanofi,EliLilly andMitsubishiTanabePharmaisalsodrivingthegrowthofthemarket.However,stringent regulatoryrequirementsandlongerapprovaltimefordrugsaswellasthelackofcomprehensive therapeuticmanagementfordiabeticnephropathyareinhibitingthegrowthofdiabeticnephropathy market.TheglobaldiabeticnephropathymarketisestimatedatUSD2,262.2millionin2014.Itislikely togrowata CAGRof5.6%from2014to2020toreachUSD3,145.9millionin2020. NorthAmericahasthelargestmarketfortheglobaldiabeticnephropathymarket.However,Intermsof growth,Asiaisthefastestgrowingregion.DiseaseModifyingTherapies(DMT)isthelargestandfastest growingmodeoftreatment,whereasACEinhibitors,isthelargestandfastestgrowingDMTofdiabetic nephropathy. NorthAmericanmarketisestimatedatUSD931.0millionin2014andisexpectedtoreachUSD1,302.0 millionin2020,growingataCAGRof5.7%from2014to2020. TheglobalDMTmarketisestimatedatUSD2,093.5millionin2014andisexpectedtoreachUSD 2,929.8millionin2020,growingataCAGRof5.8%from2014to2020. 4 PersistenceMarketResearch

  5. DiabeticNephropathyMarket-GlobalStudyon Computing:AsiatoWitnessHighestGrowthby2020 Healthcare Cloud TableofContent Chapter1Preface 1.1ReportDescription 1.2ResearchMethodology 1.3Assumptions Chapter2MarketSynopsis Chapter3Porter’sFiveForcesAnalysis 3.1BargainingPowerofSuppliers 3.2BargainingPowerofBuyers 3.3ThreatofNewEntrants 3.4ThreatofSubstitutes 3.5IntensityofRivalry 5 PersistenceMarketResearch

  6. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 Chapter4IndustryOverview 4.1MarketDefinition 4.2MarketDrivers 4.2.1Increasingprevalenceofdiabetes 4.2.2Globallyrisingobesityincreasingtheprevalenceofdiabetes 4.2.3IncreasingR&Dinvestmentsindrugdiscoveryanddevelopment 4.2.4Risingawarenessamongpeopleaboutdiabetesandkidney-relateddisorders 4.3ImpactAnalysisofMarketDrivers 4.4MarketRestraints 4.4.1Strictregulatoryrequirementsandlongapprovaltimefordrugs 4.4.2Lackofcomprehensivetherapeuticmanagementfordiabeticnephropathy 4.5ImpactAnalysisofMarketRestraints 4.6MarketTrends 4.6.1Increasingusageofcombinationtherapyisgainingpopularityindiabeticnephropathymarket Chapter5GlobalMarketSizeandForecast Chapter6MarketSizeandForecastbyModeofTreatment 6.1DiseaseModifyingTherapies 6.1.1Angiotensin-ConvertingEnzymeInhibitors 6.1.2AngiotensinReceptorBlockers 6.1.3Diuretics 6.1.4CalciumChannelBlockers 6.1.5ReninInhibitors 6.1.6ConnectiveTissueGrowthFactorInhibitors 6.1.7AntioxidantInflammationModulator 6.1.8MonocyteChemoattractantProteinsInhibitor 6.1.9Endothelin-AReceptorAntagonist 6.1.10GProtein-CoupledReceptors 6 PersistenceMarketResearch

  7. DiabeticNephropathyMarket-GlobalStudyon Computing:AsiatoWitnessHighestGrowthby2020 Healthcare Cloud Chapter7MarketSizeandForecastbyGeography 7.1NorthAmerica 7.1.1ScenariointheU.S. 7.1.2ScenarioinCanada 7.2Europe 7.2.1ScenarioinGermany 7.2.2ScenarioinFrance 7.2.3ScenariointheU.K. 7.3Asia 7.3.1ScenarioinJapan 7.3.2ScenarioinChina 7.3.3ScenarioinIndia Chapter8PipelineDrugsforDiabeticNephropathy 8.1DrugsUnderDevelopmentforDiabeticNephropathy Chapter9CompetitiveScenario 9.1CompetitiveBenchmarking Chapter10CompanyProfiles 10.1NovartisAG 10.1.1Companyoverview 10.1.2Productsandservices 10.1.3Financialperformance 10.1.4Keydevelopments 10.2Merck&Co.,Inc. 10.2.1Companyoverview 10.2.2Productsandservices 10.2.3Financialperformance 10.2.4Keydevelopments 10.3Pfizer,Inc. 7 PersistenceMarketResearch

  8. DiabeticNephropathyMarket-GlobalStudyon Computing:AsiatoWitnessHighestGrowthby2020 Healthcare Cloud 10.3.1Companyoverview 10.3.2Productsandservices 10.3.3Financialperformance 10.3.4Keydevelopments 10.4AbbottLaboratories 10.4.1Companyoverview 10.4.2Productsandservices 10.4.3Financialperformance 10.4.4Keydevelopments 10.5Sanofi 10.5.1Companyoverview 10.5.2Productsandservices 10.5.3Financialperformance 10.5.4Keydevelopments 10.6EliLillyandCompany 10.6.1Companyoverview 10.6.2Productsandsegments 10.6.3Financialperformance 10.6.4Keydevelopments 10.7ReataPharmaceuticals,Inc. 10.7.1Companyoverview 10.7.2Productsandsegments 10.7.3Financialperformance 10.7.4Keydevelopments 10.8BayerAG 10.8.1Companyoverview 10.8.2Productsandsegments 10.8.3Financialperformance 10.8.4Keydevelopments 10.9AbbVie,Inc. 10.9.1Companyoverview 8 PersistenceMarketResearch

  9. DiabeticNephropathyMarket-GlobalStudyonHealthcare Computing:AsiatoWitnessHighestGrowthby2020 Cloud 10.9.2Productsandsegments 10.9.3Financialperformance 10.9.4Keydevelopments 10.10MitsubishiTanabePharmaCorporation 10.10.1Companyoverview 10.10.2Productsandsegments 10.10.3Financialperformance 10.10.4Keydevelopments ListofTables TABLE1MarketSnapshot:Diabeticnephropathymarket,2014and2020 TABLE2Driversfordiabeticnephropathymarket:Impactanalysis TABLE3Estimatedaveragetimelinesforclinicaltrialapprovalinvariouscountries TABLE4Restraintsfordiabeticnephropathymarket:Impactanalysis TABLE5Globaldiabeticnephropathymarketsize,byregion,2010–2013(USDthousand) TABLE6Globaldiabeticnephropathymarketsize,byregion,2014–2020(USDthousand) TABLE7Globaldiabeticnephropathymarketsize,bymodeoftreatment,2010–2013(USD thousand) TABLE8Globaldiabeticnephropathymarketsize,bymodeoftreatment,2014–2020(USD thousand) TABLE9GlobalDMTmarketsize,byregion,2010–2013(USDthousand) TABLE10GlobalDMTmarketsize,byregion,2014–2020(USDthousand) TABLE11GlobalDMTmarketsize,bydrugcategories,2010–2013(USDthousand) TABLE12GlobalDMTmarketsize,bydrugcategories,2014–2020(USDthousand) TABLE13GlobalACEinhibitorsmarketsize,byregion,2010–2013(USDthousand) TABLE14GlobalACEinhibitorsmarketsize,byregion,2014–2020(USDthousand) TABLE15GlobalARBsmarketsize,byregion,2010–2013(USDthousand) TABLE16GlobalARBsmarketsize,byregion,2014–2020(USDthousand) TABLE17Globaldiureticsmarketsize,byregion,2010–2013(USDthousand) TABLE18Globaldiureticsmarketsize,byregion,2014–2020(USDthousand) TABLE19GlobalCCBsmarketsize,byregion,2010–2013(USDthousand) 9 PersistenceMarketResearch

  10. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 TABLE20GlobalCCBsmarketsize,byregion,2014–2020(USDthousand) TABLE21Globalrenininhibitorsmarketsize,byregion,2010–2013(USDthousand) TABLE22Globalrenininhibitorsmarketsize,byregion,2014–2020(USDthousand) TABLE23GlobalCTGFinhibitorsmarketsize,byregion,2010–2013(USDthousand) TABLE24GlobalCTGFinhibitorsmarketsize,byregion,2014–2020(USDthousand) TABLE25GlobalAIMmarketsize,byregion,2010–2013(USDthousand) TABLE26GlobalAIMmarketsize,byregion,2014–2020(USDthousand) TABLE27GlobalMCPinhibitorsmarketsize,byregion,2010–2013(USDthousand) TABLE28GlobalMCPinhibitorsmarketsize,byregion,2014–2020(USDthousand) TABLE29GlobalETARmarketsize,byregion,2010–2013(USDthousand) TABLE30GlobalETARmarketsize,byregion,2014–2020(USDthousand) TABLE31GlobalGPCRsmarketsize,byregion,2010–2013(USDthousand) TABLE32GlobalGPCRsmarketsize,byregion,2014–2020(USDthousand) TABLE33TheNorthAmericandiabeticnephropathymarketsize,bycountry,2010–2013(USD thousand) TABLE34TheNorthAmericandiabeticnephropathymarketsize,bycountry,2014–2020(USD thousand) TABLE35TheU.S.diabeticnephropathymarketsize,bymodeoftreatment,2010–2013(USD thousand) TABLE36TheU.S.diabeticnephropathymarketsize,bymodeoftreatment,2014–2020(USD thousand) TABLE37TheCanadiandiabeticnephropathymarketsize,bymodeoftreatment,2010–2013 (USDthousand) TABLE38TheCanadiandiabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE39TheEuropeandiabeticnephropathymarketsize,bycountry,2010–2013(USD thousand) TABLE40TheEuropeandiabeticnephropathymarketsize,bycountry,2014–2020(USD thousand) TABLE41TheGermandiabeticnephropathymarketsize,bymodeoftreatment,2010–2013(USDthousand) 10 PersistenceMarketResearch

  11. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 TABLE42TheGermandiabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE43TheFrenchdiabeticnephropathymarketsize,bymodeoftreatment,2010–2013 (USDthousand) TABLE44TheFrenchdiabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE45TheU.K.diabeticnephropathymarketsize,bymodeoftreatment,2010–2013(USD thousand) TABLE46TheU.K.diabeticnephropathymarketsize,bymodeoftreatment,2014–2020(USD thousand) TABLE47TheAsiandiabeticnephropathymarketsize,bycountry,2010–2013(USD thousand) TABLE48TheAsiandiabeticnephropathymarketsize,bycountry,2014–2020(USD thousand) TABLE49TheJapanesediabeticnephropathymarketsize,bymodeoftreatment,2010–2013 (USDthousand) TABLE50TheJapanesediabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE51TheChinesediabeticnephropathymarketsize,bymodeoftreatment,2010–2013 (USDthousand) TABLE52TheChinesediabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE53TheIndiandiabeticnephropathymarketsize,bymodeoftreatment,2010–2013 (USDthousand) TABLE54TheIndiandiabeticnephropathymarketsize,bymodeoftreatment,2014–2020 (USDthousand) TABLE55Majorpipelinedrugsfordiabeticnephropathy TABLE56ProductcategoriesofNovartisAG TABLE57ProductcategoriesofMerck&Co.,Inc. TABLE58ProductcategoriesofPfizer,Inc. TABLE59ProductcategoriesofAbbottLaboratories 11 PersistenceMarketResearch

  12. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 TABLE60ProductcategoriesofSanofi TABLE61ProductsegmentsofEliLillyandCompany TABLE62ProductcategoriesofReataPharmaceuticals,Inc. TABLE63ProductcategoriesofBayerAG TABLE64ProductcategoriesofAbbVie,Inc. TABLE65ProductcategoriesofMitsubishiTanabePharmaCorporation ListofFigures FIG.1Diabeticnephropathymarket:Porter’sfiveforcesanalysis FIG.2MajorDMTfordiabeticnephropathy FIG.3Numberofpeoplewithdiabetesmellitus(20–79years)inmajorcountries,2010,and 2030(million) FIG.4Prevalenceofoverweightandobesemalesaged30yearsandabove,2005and2015 (%) FIG.5Prevalenceofoverweightandobesefemalesaged30yearsandabove,2005and2015 (%) FIG.6Globaldiabeticnephropathymarketshare,byregion,byvalue,2013 FIG.7Globaldiabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.8GlobalDMTmarketshare,byregion,byvalue,201330 FIG.9GlobalDMTmarketshare,bydiseasecategories,byvalue,2013 FIG.10GlobalACEinhibitorsmarketshare,byregion,byvalue,2013 FIG.11GlobalARBsmarketshare,byregion,byvalue,2013 FIG.12Globaldiureticsmarketshare,byregion,byvalue,2013 FIG.13GlobalCCBsmarketshare,byregion,byvalue,2013 FIG.14Globalrenininhibitorsmarketshare,byregion,byvalue,2013 FIG.15GlobalCTGFinhibitorsmarketshare,byregion,byvalue,2013 FIG.16GlobalAIMmarketshare,byregion,byvalue,2013 FIG.17GlobalMCPinhibitorsmarketshare,byregion,byvalue,2013 FIG.18GlobalETARmarketshare,byregion,byvalue,2013 FIG.19GlobalGPCRsmarketshare,byregion,byvalue,2013 FIG.20TheNorthAmericandiabeticnephropathymarketshare,bycountry,byvalue,2013 12 PersistenceMarketResearch

  13. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 FIG.21TheU.S.diabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.22TheCanadiandiabeticnephropathymarketshare,bymodeoftreatment,byvalue, 2013 FIG.23TheEuropeandiabeticnephropathymarketshare,bycountry,byvalue,2013 FIG.24TheGermandiabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.25TheFrenchdiabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.26TheU.K.diabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.27TheAsiandiabeticnephropathymarketshare,bycountry,byvalue,2013 FIG.28TheJapanesediabeticnephropathymarketshare,bymodeoftreatment,byvalue, 2013 FIG.29TheChinesediabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.30TheIndiandiabeticnephropathymarketshare,bymodeoftreatment,byvalue,2013 FIG.31Competitivelandscapeofdiabeticnephropathymarket,2013 FIG.32NovartisAG’snetsalesandnetincome,2011–2013(USDmillion) FIG.33Merck&Co.,Inc.’ssalesandnetincome,2011–2013(USDmillion) FIG.34Pfizer,Inc.’srevenueandnetincome,2011–2013(USDmillion) FIG.35AbbottLaboratories’netsalesandnetearnings,2011–2013(USDmillion) FIG.36Sanofi’snetsalesandnetincome,2011–2013(USDmillion) FIG.37EliLillyandCompany’srevenueandnetincome,2011–2013(USDmillion) FIG.38BayerAG’snetsalesandnetincome,2011–2013(USDmillion) FIG.39AbbVie,Inc.’snetsalesandnetearnings,2011–2013(USDmillion) FIG.40MitsubishiTanabePharmaCorporation’snetsalesandnetearnings,2011–2013(USD million) AboutUs: PersistenceMarketResearchisaglobalmarketresearchfirmspecializing-syndicatedresearch,customresearch,andconsultingservices AtPersistenceMarketResearch(PMR),weareinthebusinessofacceleratingyourbusiness.Asafull- servicemarketresearchfirm,westandcommittedtobringingmoreaccuracyandspeedtoyourbusiness decisions.Fromready-to-purchasemarketresearchreportstocustomizedglobalresearchsolutions,our engagementmodelsarehighlyflexiblewithoutcompromisingonourdeep-seatedresearchvalues.Briefly 13 PersistenceMarketResearch

  14. DiabeticNephropathyMarket-GlobalStudyonHealthcareCloud Computing:AsiatoWitnessHighestGrowthby2020 stated,ourmissionistogiveyouaccesstoforecastsandtrendsanalysesthatputyouonthepathto profitability. PMR’sServicesGoBeyondGleaningData MostenterprisesbelievethatITanddatabasesareenoughtomakeanaccuratedecision.Whilewedo notdisputethat,considerthis:Howlongdoesittaketomakeanaccurate decision?Westrivetodeliverbothevenwithdemandingdeadlines. andstrategicmillion-dollar ContactUs: AddieThomes 305Broadway 7thFloor,NewYorkCity, NY10007,UnitedStates, USA-CanadaTollFree:800-961-0353 Email:sales@persistencemarketresearch.com Web:http://www.persistencemarketresearch.com Twitter:https://twitter.com/addiethomes Blog:http://persistencemarketresearchblog.wordpress.com/ 14 PersistenceMarketResearch

More Related